Enliven Therapeutics Inc (ELVN)
R&D Expense Growth
40.17%
Quarterly · Period ending:
ELVN R&D Expense Growth
Latest reported40.17%period ending
Latest reported40.17%period ending
ELVN Quarterly R&D Growth (QoQ) (0.00% → 40.17%)
Latest values, visible window
High-resolution chart · PNG
ELVN r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 40.1653% | |
| -2.6265% | |
| 16.5706% | |
| -15.1971% | |
| -13.6734% | |
| 20.1264% | |
| -2.512% | |
| 12.9183% | |
| -5.7286% | |
| 11.5331% | |
| -8.6759% | |
| 29.1313% | |
| 27.803% | |
| 44.9311% | |
| 4.7005% | |
| -1.3607% | |
| 12.438% | |
| 2.8409% | |
| -33.981% | |
| 3.2063% | |
| 41.5882% | |
| -20.5827% | |
| -6.0212% | |
| 21.1463% | |
| 35.8364% | |
| -2.5076% | |
| 15.5806% | |
| 17.7508% | |
| 22.6404% | |
| 0% |